• to decreased the risk of significant cardiovascular (heart and blood vessel) difficulties in Grownups with form two diabetes and heart problemsThis led Novo Nordisk to carry out even more investigation into increased dosages of semaglutide especially for weight administration.These pointers advocate GLP-one agonists as an additional treatment s